- Home
- ZLAB vs LPL Comparison
ZLAB vs LPL Comparison
Compare ZLAB & LPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- LPL
- Stock Information
- Founded
- ZLAB 2013
- LPL 1985
- Country
- ZLAB China
- LPL South Korea
- Employees
- ZLAB N/A
- LPL N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- LPL Industrial Machinery/Components
- Sector
- ZLAB Health Care
- LPL Technology
- Exchange
- ZLAB Nasdaq
- LPL Nasdaq
- Market Cap
- ZLAB 3.0B
- LPL 3.6B
- IPO Year
- ZLAB 2017
- LPL 2004
- Fundamental
- Price
- ZLAB $26.67
- LPL $3.39
- Analyst Decision
- ZLAB Strong Buy
- LPL Sell
- Analyst Count
- ZLAB 4
- LPL 2
- Target Price
- ZLAB $52.50
- LPL N/A
- AVG Volume (30 Days)
- ZLAB 1.1M
- LPL 198.2K
- Earning Date
- ZLAB 11-12-2024
- LPL 10-23-2024
- Dividend Yield
- ZLAB N/A
- LPL N/A
- EPS Growth
- ZLAB N/A
- LPL N/A
- EPS
- ZLAB N/A
- LPL N/A
- Revenue
- ZLAB $355,748,000.00
- LPL $19,931,616,429.00
- Revenue This Year
- ZLAB $48.50
- LPL $25.60
- Revenue Next Year
- ZLAB $47.37
- LPL $0.35
- P/E Ratio
- ZLAB N/A
- LPL N/A
- Revenue Growth
- ZLAB 35.01
- LPL 23.27
- 52 Week Low
- ZLAB $13.48
- LPL $3.33
- 52 Week High
- ZLAB $36.60
- LPL $5.66
- Technical
- Relative Strength Index (RSI)
- ZLAB 41.98
- LPL 34.81
- Support Level
- ZLAB $27.74
- LPL $3.33
- Resistance Level
- ZLAB $32.15
- LPL $3.84
- Average True Range (ATR)
- ZLAB 1.36
- LPL 0.06
- MACD
- ZLAB -0.64
- LPL -0.03
- Stochastic Oscillator
- ZLAB 3.15
- LPL 17.41
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
About LPL LG Display Co Ltd AMERICAN DEPOSITORY SHARES
LG Display Co Ltd is a South Korea-based company that is principally engaged in developing, manufacturing and selling TFT-LCD and OLED display panels. The company's products consist of panels for notebook computers, monitors, televisions, smartphones, tablets, and others. The company conducts direct sales through overseas subsidiaries in a number of countries, including the United States, Germany, Japan, Taiwan, China, and Singapore. These subsidiaries conduct sales activities and offer technical support to clients. The company generates the majority of its revenue from overseas markets, with the rest from South Korea.